Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

A quarter of a century ago, Britain shared the accolade of having the worst survival rates for cancer patients in Western ...

When I went to the hospital last year for my annual mammogram, I expected to be in and out in 60 minutes. Being a healthy ...

The following highlights showcase the most pivotal, innovative research published across multiple therapeutic areas in ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

To develop a machine learning (ML) algorithm to predict survival probabilities for patients with epithelial ovarian cancer (EOC).Data were obtained from the SEER database for women diagnosed with EOC ...

The following is a summary of “Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

Ovarian tumors, often detected incidentally, pose a diagnostic challenge that requires careful management. Decisions depend on assessing the malignancy risk and addressing patient symptoms. For benign ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...